Gene editing frees thalassemia patients from transfusions?
NCT ID NCT06024876
First seen Feb 13, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This early study tested a new gene therapy (CS-101) in 5 people with beta-thalassemia, a blood disorder requiring frequent transfusions. The treatment uses the patient's own stem cells, edited to produce healthy red blood cells. The main goals were safety and whether patients could stop needing transfusions for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
Conditions
Explore the condition pages connected to this study.